Upregulation of DCLK1 is clinically associated with the aggressiveness and poor prognosis of several cancers, whereas targeting DCLK1 via a specific monoclonal antibody can block cancer cell invasion and metastasis, thus suggestive of a potential therapeutic target for DCLK1 in cancer metastasis [15, 17]. The gene discussed is DCLK1; the disease is cancer.